IOP sensor successfully implanted in first patient

Article

Implandata Ophthalmic Products GmbH (Implandata) says it has successfully implanted its EyeMate intraocular pressure (IOP) sensor implant in a first patient in Europe undergoing keratoprosthesis surgery.

Implandata Ophthalmic Products GmbH (Implandata) says it has successfully implanted its EyeMate IOP sensor in a first patient in Europe undergoing keratoprosthesis surgery.

The implantation was performed by study principal investigator Prof. Thomas Neuhann, medical director
and founder of the Laser Eye Center Munich, within the sponsor-initiated ARGOS-KP01 study.

More in this issue: Visual function linked to preBCVA in AMD cataract patients

Implandata’s telemetrically powered EyeMate IOP sensor implant allows for non-invasive measurement and monitoring of IOP in keratoprosthesis patients.

In this first implantation, EyeMate was placed in the patient’s eye at the same time the patient underwent the keratoprosthesis implantation. The sensor allows the patient’s IOP to be measured at any chosen frequency, either continuously or on demand at specific times. Patients can perform the measurements themselves, under the conditions of everyday life.

“Elevated IOP is a main issue with keratoprosthesis patients. Approximately two-thirds of these patients already do have glaucoma preoperatively and management of secondary glaucoma remains a major challenge postoperatively,” Prof. Neuhann said. “It is a breakthrough to obtain IOP information any time, with ease and at a quality which otherwise would only be available by performing invasive IOP measurements.”

 

The EyeMate is not yet CE marked or FDA approved. In the ongoing ARGOS-KP01 pre-market study, Implandata is seeking to create clinical data to approach the CE conformity process for use of the EyeMate sensor in keratoprosthesis patients. The company also is currently conducting in parallel its ARGOS-02 study, in which the EyeMate is being tested in primary open-angle glaucoma patients undergoing cataract surgery. Implandata said it is planning to conduct additional clinical studies in Europe and North America to validate complementary product versions for broader glaucoma applications.

http://www.implandata.com/Implandata Ophthalmic Products GmbH is a privately held medical device company founded in 2010 and headquartered in Hannover, Germany and Wilmington, DE, USA. For more information, go to Implandata Ophthalmic Products GmbH.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.